Wei LIU, CEO of BioMap, points out that while AI is accelerating innovation in biotech, it still faces three major challenges: knowledge gaps, high validation costs, and data scarcity. Since its founding, BioMap has been committed to building foundational models for life sciences. Its latest model, xTrimo V3, boasts over 210 billion parameters and is designed to decode the “language of life.” With this, BioMap can generate novel therapies, such as programmable antibodies with built-in sensing functions. The next goal? Seeing the first AI-designed drugs enter clinical trials!
Read the full interview article here: https://bit.ly/4dXdbwd
3views
